Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Meilleure Health International Industry Group Limited (2327.HK)
Admiralty, HK
Meilleure Health International Industry Group Limited functions as an investment holding company, overseeing a broad spectrum of ventures in Hong Kong, the People's Republic of China, and other international markets. Its diverse operations include industrial hemp, healthcare-related services, trading, various agency services, and both property investment/leasing and development. The company actively engages in the commerce of construction supplies, the creation and sale of residential real estate, property asset management, and the distribution of health-related goods. Furthermore, it provides real estate brokerage, services focused on the application of cannabidiol (CBD) derivatives, and comprehensive health management offerings, such as anti-aging treatments, aesthetic medicine, and general wellness consulting. It also acts as an agent for healthcare product sales. Formerly known as U-Home Group Holdings Limited, the company rebranded to Meilleure Health International Industry Group Limited in March 2017. Its primary corporate office is located in Admiralty, Hong Kong.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +11.76% | +1.79% | +7.55% | -3.39% | +1.79% | -32.14% | -12.31% | +90.23% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Conglomerates: +6.1%-27.9% Q4'25: -65.0% (vs Q4'23)
-
EPS growth Conglomerates: +16.9%+17.7% ★ Q4'25: +1.8% (vs Q4'23)
-
FCF margin FCF growth · Conglomerates: +35.9%-175.7% Q4'25: -192.3% (vs Q4'23)
-
EBIT margin Conglomerates: +9.0%-26.6% Q4'25: -55.7% (vs Q4'23)
-
ROIC Conglomerates: +4.7%-0.5% Q4'25: -1.6% (vs Q4'23)
-
Share dilution Conglomerates: +0.0%-0.7% ★ Q4'25: -0.8% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Conglomerates: 1.28×-42.45× Q4'25: -9.09× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2019 actual |
Dec 2020 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. |
Dec 2027 1 Rev. Ana. |
|---|---|---|---|---|---|
| Revenue |
234.78M
est: 245.00M (-4.2%)
|
265.14M
est: 266.00M (-0.3%)
|
36.52M
est: 245.00M (-85.1%)
|
245.00M
245.00M – 245.00M
+0.0% YoY
|
266.00M
266.00M – 266.00M
+8.6% YoY
|
| EBITDA |
12.38M
est: 143.68M (-91.4%)
|
129.38M
est: 156.00M (-17.1%)
|
-8.97M
est: 107.73M (-108.3%)
|
107.73M
107.73M – 107.73M
+0.0% YoY
|
116.97M
116.97M – 116.97M
+8.6% YoY
|
| EBIT |
11.05M
est: 138.95M (-92.0%)
|
121.47M
est: 150.87M (-19.5%)
|
-9.71M
est: 103.48M (-109.4%)
|
103.48M
103.48M – 103.48M
+0.0% YoY
|
112.34M
112.34M – 112.34M
+8.6% YoY
|
| Net Income |
-23.01M
|
83.44M
|
37.98M
|
—
— – —
|
—
— – —
|
| SGA |
39.86M
est: 77.62M (-48.7%)
|
50.41M
est: 84.28M (-40.2%)
|
31.17M
est: 110.14M (-71.7%)
|
110.14M
110.14M – 110.14M
+0.0% YoY
|
119.58M
119.58M – 119.58M
+8.6% YoY
|
| EPS |
-0.01
|
0.02
|
0.01
|
—
— – —
|
—
— – —
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B- | 3/5 | 1/5 | 2/5 | 3/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-28 | B- | 3/5 | 1/5 | 2/5 | 3/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-27 | B- | 3/5 | 1/5 | 2/5 | 3/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-26 | B- | 3/5 | 1/5 | 2/5 | 3/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-22 | B- | 3/5 | 1/5 | 2/5 | 3/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-21 | B- | 3/5 | 1/5 | 2/5 | 3/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-20 | B- | 3/5 | 1/5 | 2/5 | 3/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-19 | B- | 3/5 | 1/5 | 2/5 | 3/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-18 | B- | 3/5 | 1/5 | 2/5 | 3/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-15 | B- | 2/5 | 1/5 | 2/5 | 3/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-14 | B- | 2/5 | 1/5 | 2/5 | 3/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-13 | B- | 2/5 | 1/5 | 2/5 | 3/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-11 | B- | 2/5 | 1/5 | 2/5 | 3/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-08 | B- | 2/5 | 1/5 | 2/5 | 3/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-07 | B- | 2/5 | 1/5 | 2/5 | 3/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-06 | B- | 2/5 | 1/5 | 2/5 | 3/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-05 | B- | 2/5 | 1/5 | 2/5 | 3/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-04 | B- | 2/5 | 1/5 | 2/5 | 3/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-30 | B- | 3/5 | 1/5 | 2/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-29 | B- | 3/5 | 1/5 | 2/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-28 | B- | 3/5 | 1/5 | 2/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-27 | B- | 3/5 | 1/5 | 2/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-24 | B- | 3/5 | 1/5 | 2/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-23 | B- | 3/5 | 1/5 | 2/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-21 | B- | 3/5 | 1/5 | 2/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-20 | B- | 3/5 | 1/5 | 2/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-17 | B- | 3/5 | 1/5 | 2/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-16 | B- | 3/5 | 1/5 | 2/5 | 4/5 | 2/5 | 2/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Wen Chuan Zhou | CEO & Executive Vice Chairman of the Board | 1M | female |
| Wentao Zeng | Executive Co-Chairman of the Board | 800.0K | — |
| Xuzhou Zhou | Executive Co-Chairman of the Board | 800.0K | male |
| Kwai Kwan Tsoi | Joint Company Secretary | — | male |
| Mei Yi Chu | Joint Company Secretary | — | female |
| Shu Pai Li | Chief Financial Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 2327.HK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
